Roche's Parkinson's drug misses main goal in mid-stage trial

Roche's prasinezumab drug for Parkinson's disease did not meet trial objectives, marking a significant setback, while showing potential efficacy and plans for further exploration.

Poseida shares surge on $1.5 billion Roche acquisition deal

Roche set to acquire Poseida Therapeutics for up to $1.5 billion

Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 billion deal

Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job

U.S. drugmaker shares fell after Trump appointed Robert F. Kennedy Jr. to lead health, raising investor concerns over vaccine policies and agency oversight.

Roche reports Q3 sales growth, driven by strong pharma performance and Actemra

Roche reported slight Q3 sales growth driven by pharmaceuticals, mainly Actemra, despite some challenges. Future earnings expectations remain positive amidst pipeline adjustments and competitive landscape.

Roche comes out against allowing takeover of drug manufacturer Catalent

Roche's CEO urged authorities to block Novo Nordisk's acquisition of Catalent, citing potential competition issues in the weight-loss drug market, raising concerns for smaller competitors.